Cholangiocarcinoma



Cholangiocarcinoma





DEFINITION:



  • Bile duct cancers that arise from the epithelial cells of the bile ducts (does not include gallbladder or ampullary cancer)


  • Classification:



    • Intrahepatic: originate from small or large intrahepatic ducts proximal to right and left hepatic duct bifurcation


    • Perihilar Extrahepatic (65%): includes the confluence of the right and left hepatic duct bifurcation



      • Further classified according to involvement of the hepatic ducts: Bismuth Classification (Figure)


      • Type I: tumors below the confluence


      • Type II: tumors reaching the confluence


      • Type IIIA & IIIB: tumors occluding the common hepatic and Right or Left hepatic duct


      • Type IV: tumors that are multicentric or involving confluence and both hepatic ducts


      • Klatskin tumors: term used to define involvement of the common hepatic duct bifurcation


    • Distal Extrahepatic: from common bile duct to the point where the bile duct lies posterior to the duodenum





image



EPIDEMIOLOGY:



  • Rare; Represent 3% of GI malignancies with an incidence of 1-2 per 100,000; ♂ > ♀


  • Nearly all (>90%) are adenocarcinomas, further divided into:



    • Sclerosing: invade bile duct early, associated with low respectability and cure rates


    • Nodular: constricting annular lesion of the bile duct and highly invasive


    • Papillary: rare, present as bulky masses in the common bile duct and early presenting symptoms


ETIOLOGIES:



  • Several risk factors identified:



    • PSC/UC patients represents 30% of all diagnosed cholangiocarcinoma (lifetime risk is 10-15% for PSC/UC patient)



      • Difficult to diagnose since biliary tree is abnormal to begin with; >30% diagnosed within 2 years of PSC diagnosis


      • Screening suggested by some clinicians: US and CA19-9 annually or semi-annually if cirrhotic


      • A CA19-9 >100 U/ml and a malignant appearing stricture has been used in lieu of tissue diagnosis to begin treatment



    • Choledochal cysts, Caroli’s syndrome, Congenital hepatic fibrosis: 15% risk of malignant change (average age at diagnosis is 34)



      • Unclear why; could possibly be related to biliary stasis or chronic inflammation via pancreatic juice reflux


    • Parasitic infection:



      • Infection with liver flukes (Clonorchis and Opisthorchis) is associated with intrahepatic bile duct cancer, especially in Asia


      • Consuming undercooked fish leads to adult worms laying eggs in the biliary system leading to chronic inflammation


    • Hepatolithiasis and Cholelithiasis:



      • Unclear if gallstones really predispose to cholangiocarcinoma


      • There is a clear association with intrahepatic stones (much higher prevalence in Asia) and cholangiocarcinoma


    • Toxic exposures:



      • Thorotrast, an old radiologic contrast agent banded in the 1960’s showed a clear association


      • Association of smoking and alcohol are conflicting as is occupational exposures (auto, rubber, wood)


    • Lynch syndrome II and Multiple biliary papillomatosis



      • Have an associated increased risk


    • Chronic liver disease:



      • HBV, HCV, and Cirrhosis regardless of etiology are believed to be risk factors


    • Other possible risks:



      • Diabetes, HIV infection


PATHOPHYSIOLOGY:



  • Conversion from normal to malignant bile epithelium is probably a stepwise accumulation of genetic mishaps similar to colon cancer



    • Evidence of such genetic abnormalities is poorly understood


    • Evidence of oncogenes (K-ras) and tumor suppressor genes (p53) have been described


CLINICAL MANIFESTATIONS/PHYSICAL EXAM:

Aug 24, 2016 | Posted by in GASTROENTEROLOGY | Comments Off on Cholangiocarcinoma

Full access? Get Clinical Tree

Get Clinical Tree app for offline access